Peregrine Capital Management LLC Acadia Pharmaceuticals Inc Transaction History

Peregrine Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$25.02 - $54.99 $4.29 Million - $9.42 Million	-171,291 Closed	0 $0
Q4 2020 Jan 19, 2021	SELL	$41.04 - $56.79 $689,389 - $953,958	-16,798 Reduced 8.93%	171,291 $9.16 Million
Q3 2020 Oct 20, 2020	SELL	$36.42 - $57.0 $1.37 Million - $2.14 Million	-37,568 Reduced 16.65%	188,089 $0
Q2 2020 Jul 30, 2020	SELL	$39.26 - $52.73 $7.2 Million - $9.67 Million	-183,297 Reduced 44.82%	225,657 $0
Q1 2020 Apr 17, 2020	BUY	$31.65 - $46.87 $1.18 Million - $1.74 Million	37,177 Added 10.0%	408,954 $0
Q4 2019 Jan 16, 2020	SELL	$36.21 - $51.4 $813,855 - $1.16 Million	-22,476 Reduced 5.7%	371,777 $0
Q3 2019 Oct 16, 2019	SELL	$22.22 - $44.01 $3.2 Million - $6.34 Million	-144,025 Reduced 26.76%	394,253 $0
Q2 2019 Jul 18, 2019	SELL	$23.32 - $28.12 $27,191 - $32,787	-1,166 Reduced 0.22%	538,278 $0
Q1 2019 Apr 12, 2019	SELL	$16.17 - $27.38 $2.27 Million - $3.84 Million	-140,161 Reduced 20.62%	539,444 $0
Q4 2018 Jan 17, 2019	SELL	$14.32 - $22.92 $1.06 Million - $1.69 Million	-73,709 Reduced 9.78%	679,605 $0
Q3 2018 Oct 18, 2018	BUY	$13.03 - $21.81 $9.82 Million - $16.4 Million	753,314 New	753,314 $0

280

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.65B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Peregrine Capital Management LLC with notifications on news.